INmune Bio Advances Ebstrocelâ„¢ Toward Potential UK Approval in Mid-2027

Go back to INmune Bio Advances Ebstrocelâ„¢ Toward Potential UK Approval in Mid-2027
(NASDAQ: INMB) Delayed: 1.61 --0 (-0%)
Previous Close $1.61    52 Week High $ 
Open $1.61    52 Week Low $ 
Day High $1.61    P/E N/A 
Day Low $1.61    EPS $ 
Volume 1